ECAP Third Report

The third report from the Endometrial Cancer Audit Pilot was published in May 2026. ​

It summarises routes to diagnosis, tumour genomic testing and immunotherapy use among women diagnosed with endometrial cancer in England. It describes national patterns and differences between groups of women and between different parts of England.

Key Findings:​

1. Most women diagnosed between 2017 and 2019 were diagnosed following a two-week wait referral (62%). Emergency presentation was the third most common route to diagnosis and accounted for 7% of diagnoses.
2. Emergency presentation was more common in some groups of women, including older women, those living in more deprived areas, and those who had higher levels of comorbidity. Some variation was also seen by ethnic group, with highest observed rates and largest odds of diagnosis via emergency presentation being among women in the black ethnic group (compared with women in the white ethnic group).
3. Records of tumour genomic testing increased markedly from 2020, with around 80% of women diagnosed in 2023 having at least one test recorded. These findings should be interpreted cautiously, as variation may reflect data completeness and reporting as well as change in clinical practice.
4. Records of immunotherapy use were low overall but increased over time among women diagnosed between 2017 and 2023.
5. Some geographic variation was seen across the report. For emergency presentation and immunotherapy, much of this appeared to reflect differences in patient and tumour characteristics between regions.

The analysis for this report did not involve collecting new data. Instead, it linked existing NHS datasets that capture clinical data on cancer diagnosis and treatment in routine day-to-day practice in NHS hospitals in England. These included the National Cancer Registration Dataset (NCRD), route to diagnosis data, pathology test records submitted by hospital pathology laboratories and the Systemic Anti-Cancer Therapy dataset (SACT).

Different datasets were used for different parts of the report. The NCRD was used to identify women diagnosed with endometrial cancer. Routes to diagnosis data were used to show how women entered specialist care. Pathology test records were used to identify recorded tumour genomic tests. The SACT dataset and the treatment table within the NCRD were used to identify immunotherapy treatment.

This report provides a national picture of diagnosis routes, tumour genomic testing and immunotherapy use for endometrial cancer in England. It is intended to describe patterns in the available data, including differences between areas of England and between groups of women. The findings presented in this report can be downloaded below.​ Trust-level findings are also available to providers through the CancerStats2 portal. (This opens in a new window).

*Please note that this platform requires an N3/HSCN secure network connection and password access which can be authorised for relevant NHS staff by provider trust cancer management teams.​